We then used ASTCT grades to predict management according to current guidelines for DLBCL pts (axi-cel and tisa-cel insert packages, CARTOX and NCCN guidelines) and compare it to the actual treatment received at our center. Results According to the ASTCT grading, B-ALL pts had 87% CRS (...
In general, we agree with this approach because it initiates CRS management earlier, allowing for earlier resolution while still preserving efficacy. We also differentiate this practice shift from the prophylactic or preemptive use of tocilizumab, which remains experimental. Nonetheless, the goal of ...
Professional societies have published expert panel consensus standards for the management of toxicities such as CRS and ICANS [10, 11, 12]. In contrast, REMS or product-specific guidelines developed by the manufacturer should focus on unusual, product-specific toxicities. For example, ciltacabtagene...